CLN6

Across TCGA pan-cancer cohorts, CLN6 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CLN6’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where CLN6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLN6 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

PDAC, LSCC, and COAD are the cancer types where CLN6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLN6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+0.986	<.001	6	view →
LSCC	Male	II,III,IV	+0.502	<.001	6	view →
COAD	All	IV	+1.113	.028	2	view →
CCRCC	Male	All	−0.215	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CLN6–PDAC

Open the PDAC breakdown →